Crinetics Pharmaceuticals
CRNX
CRNX was delisted on the 31st of August, 2026.
85 hedge funds and large institutions have $429M invested in Crinetics Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 33 increasing their positions, 15 reducing their positions, and 6 closing their positions.
233% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 6
120% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 15
20% more funds holding
Funds holding: 71 → 85 (+14)
0.16% more ownership
Funds ownership: 92.26% → 92.42% (+0.16%)
10% less capital invested
Capital invested by funds: $475M → $429M (-$46.1M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.93M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$8.07M |
| 3 |
BlackRock
New York
|
+$4.38M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$4.38M |
| 5 |
Morgan Stanley
New York
|
+$2.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$24.6M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$13.2M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.76M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$784K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$592K |
CRNX Hedge Fund Activity: Q4 2020 in Review
85 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q4 2020, worth a combined $429M — down 9.7% from $475M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new CRNX positions and 6 closed out — a net gain of 14 holders — while 33 added to existing stakes and 15 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $9.93M. The largest seller was RA Capital Management, cutting an estimated $24.6M.
- 85 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q4 2020, up from 71 in Q3 2020.
- Funds reported $429M of Crinetics Pharmaceuticals stock for Q4 2020, down 9.7% quarter-over-quarter.
- 20 funds opened new Crinetics Pharmaceuticals positions in Q4 2020 and 6 closed out, a net change of +14 holders.
- The largest Crinetics Pharmaceuticals buyer in Q4 2020 was Point72 Asset Management, an estimated $9.93M added.
- The largest Crinetics Pharmaceuticals seller in Q4 2020 was RA Capital Management, an estimated $24.6M sold.
Based on aggregated 13F filings for Q4 2020.